Injection of Tenoxicam Versus Arthrocentesis Alone in the Treatment of Temporomandibular Joint Osteoarthritis
Status:
Completed
Trial end date:
2022-04-21
Target enrollment:
Participant gender:
Summary
The aim of the study is to examine the effectiveness of arthrocentesis plus tenoxicam
injection and to compare it with arthrocentesis alone in patients with TMJ-OA.
Thirty patients with TMJ-OA who were treated randomly with either arthrocentesis plus
tenoxicam injection (TX group) or arthrocentesis alone (control group) were examined. Maximum
mouth opening (MMO), visual analog scale (VAS) pain values, and joint sounds were the outcome
variables, which were evaluated at pre-treatment and at 1, 4, 12, and 24 weeks after
treatment.